A Phase 3 interventional study of Quemliclustat and Placebo in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Arcus Biosciences, Inc.. Active, not recruiting at 111 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Arcus Biosciences, Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Have not been previously treated for PDAC in the metastatic setting.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Quemliclustat, nab-paclitaxel and gemcitabine will be administered by IV infusion
Drug: Quemliclustat · Drug: Nab-paclitaxel · Drug: Gemcitabine
Placebo, nab-paclitaxel and gemcitabine will be administered by IV infusion
Drug: Placebo · Drug: Nab-paclitaxel · Drug: Gemcitabine
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Overall Survival (OS)
Time frame: Up to 72 months
Progression-free Survival (PFS) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 72 months
Objective response rate (ORR) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 72 months
Duration of response (DoR) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 72 months
Disease Control Rate (DCR) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 72 months
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 72 months
Showing the first 100 of 111 sites across 13 countries.
Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan \[SAP\], Clinical Study Report \[CSR\]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Supporting information: Study protocol, Sap, Csr
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arcus Biosciences, Inc.